Processa Pharmaceuticals to Present at Access to Giving Virtual Conference on July 14, 2021 at 10:30 a.m. ET
July 06, 2021 08:15 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, July 06, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced today that the company will present at Access to Giving Virtual Conference. The presentation...
Processa Set to Join Russell Microcap® Index
June 08, 2021 09:15 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, June 08, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve...
Processa Pharmaceuticals to Participate in Upcoming Investor Conferences
May 26, 2021 09:15 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, May 26, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve...
Processa Pharmaceuticals Announces First Patient Dosed in its Randomized Double-Blind, Placebo-Controlled Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica
May 20, 2021 16:05 ET
|
Processa Pharmaceuticals, Inc.
~Processa’s trial is currently enrolling patients with ulcerated Necrobiosis Lipoidica. Detailed information on the trial can be located on clinicaltrials.gov NCT#: 04800562.~ HANOVER, MD., May 20,...
Processa Pharmaceuticals Schedules Conference Call to Discuss First Quarter Results and Provide Drug Development Update on May 13 at 5:30 p.m. EST
May 07, 2021 08:30 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD., May 07, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve...
Processa Pharmaceuticals Announces Year end 2020 Results and Provides Corporate Update
March 25, 2021 16:06 ET
|
Processa Pharmaceuticals, Inc.
Clinical drug pipeline is funded and targeting major milestones in 2021 HANOVER, Md., March 25, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"),...
Processa Pharmaceuticals Schedules Conference Call to Discuss Fourth Quarter Results and Provide Drug Development Update on March 25 at 5:30 p.m. ET
March 22, 2021 09:15 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD., March 22, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to...
Processa Announces Sites Selected for Phase 2B Clinical Trial to Treat Patients with Ulcerated Necrobiosis Lipoidica
March 17, 2021 09:15 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, March 17, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage company developing drugs for patients who have unmet medical...
Processa Pharmaceuticals Announces Closing of a $10.2 Million Private Placement
March 02, 2021 09:15 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, March 02, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) is pleased to announce it has closed its previously announced private placement to institutional and...
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
February 17, 2021 08:00 ET
|
Processa Pharmaceuticals, Inc.
Strengthened Financial Position Supports Execution Through 2023 HANOVER, MD., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a...